Sign In
Buy CTMX
$3.16
-0.290 (-8.41%)
At Close: Jun 02, 2026
CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript
08:44am, Friday, 08'th Nov 2024
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Chris Ogden - CFO Sean A. McCarthy - Chairman and CEO Conference Call Partici
CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates
06:56pm, Thursday, 07'th Nov 2024
CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to earnings of $0.04 per share a year a
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
04:10pm, Thursday, 07'th Nov 2024
- Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. -
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announce
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
04:10pm, Thursday, 08'th Aug 2024
- CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end of 2024 -
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
08:00am, Tuesday, 18'th Jun 2024
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
04:15pm, Monday, 17'th Jun 2024
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promoti
Buy Alert: 3 Penny Stocks That Will Explode in 2024
06:00am, Wednesday, 05'th Jun 2024
When the term penny stocks to buy is thrown around, ideas of high-risk-high-reward, overnight wealth generation and potential scams may come to mind. However, investing in carefully-selected penny sto
No Memes, Ma'am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.
06:25am, Wednesday, 29'th May 2024
Not long ago, GameStop (NYSE: GME ) stock soared and then tanked on the meme-stock waves. A company that went along for the ride was CytomX Therapeutics (NASDAQ: CTMX ), as CytomX Therapeutics stock t
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
04:05pm, Wednesday, 22'nd May 2024
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced
CytomX Therapeutics Announces New Employment Inducement Grants
04:15pm, Thursday, 16'th May 2024
SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May
Why Is CytomX (CTMX) Stock Down 43% Today?
11:56am, Thursday, 09'th May 2024
CytomX Therapeutics (NASDAQ: CTMX ) stock is taking a beating on Thursday following a clinical trial update from the oncology-focused biopharmaceutical company. CytomX Therapeutics latest clinical tra
CytomX stock down 30% despite encouraging cancer study results
09:10am, Thursday, 09'th May 2024
CytomX Therapeutics Inc reported favourable results for its ongoing trial of CX-904 on Thursday. Shares of the biotech firm are still down about 30% at writing.
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
04:10pm, Wednesday, 08'th May 2024
- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall -
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
04:10pm, Wednesday, 08'th May 2024
- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors -
